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HBackground:We sought to determine the long-term performance of homograft and truncal valve after complete
repair of common arterial trunk.
Methods: From January 1964 to June 2008, 32 patients (median age, 14 days; range, 5 days to 2.5 years) under-
went primary homograft repair of common arterial trunk. Twenty-four (75%) were neonates. The homograft used
in the right ventricular outflow tract was aortic in 24 patients and pulmonary in 8 patients (mean diameter, 15.8
3.5 mm; median diameter, 16 mm [range, 8–24 mm]). The median follow-up was 24.5 years (range, 5.6 months to
43.5 years).
Results: There were 3 hospital deaths and 1 late death. The actuarial survival at 30 years was 83.1% 6.6%. Of
the 28 survivors, 25 reoperations were performed in 19 (76%) patients. The mean and median times to homograft
reoperation were 11.5  7.4 and 12.1 years (range, 1.0–26.1 years), respectively. Overall freedom from homo-
graft reoperation after 10, 20, and 30 years was 68.4%  8.7%, 37.4%  9.5%, and 26.7%  9.3%, respec-
tively. Twelve patients retained the original homografts at a median follow-up of 16.4 years (range, 0–30.2 years).
Six underwent a truncal valve replacement with a mechanical prosthesis at a median of 10.5 years (range, 3.4–22
years) after truncus repair. Freedom from truncal valve replacement at 10 and 30 years was 93.1%  4.7% and
81.8%  8.9%, respectively. In the 22 surviving patients who did not undergo truncal valve replacement, the
peak truncal valve gradient was 8.9  8.3 mm Hg at a median follow-up of 24.5 years (range, 5.6 months to
32.9 years). At the last follow-up, 27 (96.4%) patients had good left ventricular function, and 24 patients
(85.7%) were New York Heart Association class I.
Conclusions: Oversizing the homograft at the time of the initial repair can lead to a homograft lasting more than
12 years. During long-term follow-up, 20% of patients require truncal valve replacement. (J Thorac Cardiovasc
Surg 2010;140:325-9)Common arterial trunk (CAT) is a rare abnormality that
accounts for less than 3% of congenital cardiac disease.1-3
Without surgical intervention, the mortality of patients
with CAT approaches 80% at 1 year.2,3 Reconstruction of
the right ventricular outflow tract (RVOT) is necessary to
establish a separate pulmonary circulation and is one of
the most challenging aspects of surgical intervention in
patients with CAT. A range of RVOT reconstruction grafts
are available, but at present, homografts are considered the
gold standard.4 Homografts offer good durability, low rates
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The Journal of Thoracic and CaAortic or pulmonary homografts can be used for RVOT
reconstruction, and it is arguable which is superior.9,10
Recently, valved xenografts, such as Contegra (Medtronic,
Inc, Minneapolis, Minn), have come to the fore mainly as
a result of their off-the-shelf availability and broad range
of sizes.11 Doubts remain over the long-term durability of
these implants, although in the medium term Contegra
conduits appear comparable with homografts.11,12
Outcomes after surgical intervention for CAThave tradition-
ally beenmeasured in termsof short- and long-termsurvival. In-
deed, most deaths occur early in the postoperative period or are
related to later reintervention.13,14 Actuarial survival has been
reported as 90% at 5 years, 85% at 10 years, and 83% at 15
years in those surviving discharge from the hospital, and this
is broadly consistent with other long-term studies.14-16 With
an increase in mortality being linked to revision surgery, the
time to reintervention for graft dysfunction is an important
outcome measure in patients with CAT. The principle factor
associated with a shorter time to conduit replacement is
smaller conduit size at primary intervention.14,17 Other
common indications for reintervention include homograftrdiovascular Surgery c Volume 140, Number 2 325
Abbreviations and Acronyms
CAT ¼ common arterial trunk
MPA ¼ main pulmonary artery
NYHA ¼ New York Heart Association
PA ¼ pulmonary artery
RA ¼ right atrium
RVOT ¼ right ventricular outflow tract
Congenital Heart Disease Vohra et al
C
H
Dstenosis or calcification, truncal valve regurgitation, and
infective endocarditis. Functional outcomes are also of
clinical importance and include the presence of congestive
cardiac failure and the effect of symptoms on health-related
quality of life. In this study we report our 40-year experience
of CAT repair with homografts. To our knowledge, this is the
longest follow-up reported.MATERIALS AND METHODS
Patients who had undergone primary repair of CAT with a homograft
(aortic or pulmonary) between January 1964 and June 2008 were included
in this study. Data (including follow-up) were collected from computerized
databases (HeartSuite; Systeria Ltd, Glasgow, United Kingdom) and patient
notes, retrospectively. Patient consent was waived by the institutional board.
Thirty-two patients were identified with a median age of 14 days (range,
5 days to 2.5 years; Table 1). Of these, the majority underwent primary
repair as neonates in the first month of life (n¼ 24, 75%). The 8 remaining
patients underwent repair beyond 1 month of life (1–3 months, n ¼ 3; 3–6
months, n ¼ 3;>1 year, n ¼ 2). The reasons for late primary repair were
delayed referral (n ¼ 7) and severe noncardiac disease necessitating treat-
ment before CAT repair (n ¼ 1).
Several CAT anatomic variants were seen in our series, and these were
classified according to the standard system.18 The majority of patients
(n ¼ 24, 75%) had A1 CAT, with a single pulmonary trunk arising from
the common trunk. Six (18.7%) patients had A2 CAT, with separate origins
of the left and right branch pulmonary arteries (PAs) from the lateral aspects
of the common trunk. The remaining 2 (6.2%) patients were classified as
having A4 CAT, with an associated interrupted aortic arch. Surgical inter-
vention typically involved median sternotomy, cardiopulmonary bypass
with moderate hypothermia, and crystalloid cardioplegic arrest. The com-
mon trunk and truncal valve were committed to the left ventricle with clo-
sure of any associated ventricular septal defect. The RVOT was
subsequently reconstructed with either an aortic (n¼ 25, 78.1%) or pulmo-
nary (n ¼ 7, 21.9%) cryopreserved homograft. The mean diameter of the
homografts was 15.8  3.5 mm, and the median diameter was 16 mm
(range, 8–24 mm). In the 24 neonates the median size of the homografts
used was 15 mm, with a range between 8 and 20 mm. Concomitant proce-
dures were performed in several cases and included ventricular septal defect
closure (n ¼ 6), aortic root replacement for truncal valve regurgitation
(n ¼ 1), and repair of an interrupted aortic arch (n ¼ 2). Indications for ho-
mograft reoperation included pulmonary regurgitation, stenosis with symp-
toms, or both; asymptomatic severe pulmonary regurgitation; and
pulmonary stenosis with a gradient of greater than 50 mm Hg. Follow-up
was complete for all patients and included assessment of functional status
(New York Heart Association [NYHA] classification).
Operative Details
Surgical intervention was performed through a median sternotomy.
Cardiopulmonary bypass was established with bicaval and distal ascending326 The Journal of Thoracic and Cardiovascular Surgaortic cannulation. The patient was cooled to 28C. Deep hypothermic
circulatory arrest was only used if intervention on the aortic arch was per-
formed. The patient was cooled to 18C in these cases. The ductus arteriosus
was ligated and divided if patent. Snares were placed around the right and
left PAs and cavae, and the heart was arrested with intermittent antegrade
cold blood cardioplegia. Topical cooling was applied. The right atrium
(RA) was opened parallel to the atrioventricular groove, and a vent was
placed through a patent foramen ovale (created if necessary). The main pul-
monary artery (MPA) was divided from the aorta, and the incision in the
truncus was continued to the right in a horizontal fashion above the truncal
valve. The truncal valve was then inspected, and the appropriate procedure
was performed, if required (see below). The aorta was then closed with con-
tinuous 6–0 Prolene sutures (Ethicon, Inc, Somerville, NJ). A bovine peri-
cardial patch on the aorta was applied only if required. Cardioplegia was
given, which also tests the truncal valve competence. The ventricular septal
defect was then inspected through the RA and, if present, was closed with an
autologous pericardial patch with continuous 5–0 Prolene sutures. Next the
bifurcation of the MPA was inspected. If small/stenosed, the right PA, left
PA, or both was augmented with an autologous pericardial patch. We used
antibiotic-sterilized homografts until April 2001 and cryopreserved homo-
grafts since then.
The homograft was then trimmed and anastomosed to the MPA bifurca-
tion with continuous 6–0 Prolene sutures. The proximal end of the homo-
graft was then anastomosed to a right ventriculotomy with continuous
5–0 Prolene sutures. The RA was then closed. Deairing was performed
through the aortic root, and the crossclamp was removed. Standard cardiac
surgery steps were then followed. To fit a 16-mm or larger homograft onto
a newborn heart, we anastomosed the homograft to the RVOT between the
truncal valve and the left anterior descending coronary artery. The anasto-
mosis is fashioned so that the homograft arises from the right ventricle at
an angle of 90. In this way, instead of heading straight toward the PA bi-
furcation, the homograft is directed toward the left lung. The left pleura is
then opened, enabling the homograft to swing over into the medial part of
the left pleural cavity, and is then turned back onto the PA bifurcation.
Distally, the incision/anastomosis is extended onto the left PA in a beveled
fashion. We have not had any problems with this oversizing.
Statistical Analyses
Data are expressed as frequencies, means  standard deviations, or
medians with ranges, as appropriate. Survival, time to replacement of the
homograft, and time to aortic/truncal valve replacement are expressed as
Kaplan–Meier curves. SPSS software (15.1.2 for Windows; SPSS, Inc,
Chicago, Ill) was used.RESULTS
There were 3 inpatient deaths after primary CAT repair.
The last death occurred in 1989. One patient had severe aor-
tic/truncal valve regurgitation, whereas 2 patients experi-
enced perioperative cardiac arrest. Of the latter, one had
severe hypoxic cerebral damage, and the other had recurrent
pulmonary hypertensive crises and low cardiac output. In
our series there was 1 late death with 28 long-term survivors.
Follow-up among all surviving patients was complete, with
a median follow-up time of 24.5 years (range, 5.6 months to
43.5 years). The actuarial survival at 30 years was 83.1% 
6.6% (Figure 1).
Reoperations resulted in 25 repeat procedures in 19
(76%) patients. The majority of patients underwent a single
revision (n ¼ 13); however, some patients required further
intervention (double revision, n ¼ 3; triple revision,ery c August 2010
TABLE 1. Patients’ characteristics
No. (n ¼ 32)
Median age at time of operation 14 d (range, 5 d to 2.5 y)
Sex (%)
Male 13 (40.6)
Female 19 (59.3)
CAT anatomic classification (%)
A1 24 (75)
A2 6 (18.7)
A3 0 (0.0)
A4 2 (6.2)
Type of homograft at primary operation (%)
Aortic 25 (78.1)
Pulmonary 7 (21.9)
Mortality (%) 3 (9.3)
Indication for homograft reoperation (%; n¼ 17)
Stenosis 14 (82.3)
Infective endocarditis 2 (11.8)
Thrombosis 1 (5.9)
CAT, Common arterial trunk.
Years At risk Events % free of re-
replacement
SE
0
1
5
10
15
20
30
32 0 100
28 1 96.6 3.4
24 4 82.8 7.0
19 4 68.4 8.7
13 5 49.9 9.5
9 3 37.4 9.5
2 2 26.7 9.3
Time to re-replacement of homograft (years)
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FIGURE 2. Kaplan–Meier estimate of freedom from homograft replace-
ment: number of patients at risk, percentage of patients free from homograft
replacement, and standard error (SE) as a percentage are shown.
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Dn ¼ 2). The mean and median times to homograft reopera-
tion were 11.5 7.4 and 12.1 years (range, 1.0–26.1 years),
respectively. The main indication for revision was homo-
graft stenosis (n ¼ 14), although other complications oc-
curred. We did not find any difference in terms of
durability of the pulmonary and aortic homografts. The aor-
tic homografts did not calcify and stenose earlier. Homograft
replacement was the most common reintervention (n¼ 16 in
12 patients), with 1 patient undergoing homograft repair. In
our series freedom from homograft reoperation was
68.4%  8.7% at 10 years, 37.4%  9.5% at 20 years,
and 26.7%  9.3% at 30 years (Figure 2). Indeed, 12 pa-
tients retained their original homografts at a median
follow-up of 16.4 years (range, 0–30.2 years). The peak
RVOT gradient in these patients at last follow-up was
38.9  5.3 mm Hg. One patient required balloon dilatation
of the origins of the right and left PAs, 1 patient requiredDuration free of event (years)
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Years At risk Events % survival SE 
0 32 0 100
1 4.3
5 5.2 
10 5.2 
20 5.2 
30
30 2 93.8
29 1 90.6
26 0 90.6
13 0 90.6
4 1 83.1 68.6
FIGURE 1. Kaplan–Meier estimate of survival in all patients: number of
patients at risk, percentage of patients surviving, and standard error (SE)
as a percentage are shown.
The Journal of Thoracic and Caventricular tachycardia ablation, and 1 patient required
accessory pathway ablation, occurring 22, 11, and 9.5 years
after the original operation, respectively.
Six reoperations were performed during follow-up in 5 pa-
tients for severe truncal/aortic valve regurgitation. Of these,
3 underwent truncal valve replacement alone, 1 received an
aortic root replacement, and 1 underwent an aortic valve re-
placement followed later by an aortic root replacement. The
median time to truncal valve replacement was 10.5 years
(range, 3.4–22.0 years) after truncus repair, whereas free-
dom from truncal valve replacement was 93.1%  4.7%
at 10 years and 81.8% 8.9% at 30 years among all partic-
ipants (Figure 3). In the 22 surviving patients who did not
undergo truncal valve replacement, the peak aortic truncal/
aortic valve gradient was 8.9  8.3 mm Hg at a median
follow-up of 24.5 years (range, 5.6–32.9 years). Truncal/
aortic valve regurgitation in the 20 patients was minimal
(nil/trace, n ¼ 18; mild, n ¼ 4). At final follow-up, 27
(96.4%) of the surviving patients had good left ventricular
function on echocardiographic analysis. At this stage, the
majority of patients were in NYHA class I (n ¼ 24,
85.7%). Four (10.7%) patients had slight limitation of phys-
ical activity (NYHA class II), whereas only 1 (3.6%) patient
was in NYHA class III. Complications occurred in 4 patients
by final follow-up and included cerebrovascular accident
(n¼ 1), recurrent chest infections (n¼ 1), ventricular tachy-
cardia requiring ablation therapy (n ¼ 1), and ablation of an
accessory pathway (n ¼ 1).rdiovascular Surgery c Volume 140, Number 2 327
Time to aortic valve reoperation (years)
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replacement
SE
0
5
10
15
30
Years At risk Events % free of re-
32 0 100
27 2 93.1 4.7
25 0 93.1 4.7
23 1 89.2 5.9
4 1 81.8 8.9
FIGURE 3. Kaplan–Meier estimate of freedom from truncal valve opera-
tions: number of patients at risk, percentage of patients free from truncal
valve replacement, and standard error (SE) as a percentage are shown.
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DDISCUSSION
Long-term studies of the clinical and functional outcomes
in CAT repair are needed to inform decision making when
planning surgical intervention. Early and late mortality, free-
dom from RVOT graft reintervention, and the functional
performance of the truncal valve are all important factors
that need to be taken into account. Reconstruction of the
RVOT is a key part of the procedure, with a range of grafts
available, including pulmonary or aortic homografts, por-
cine xenografts, and valved bovine jugular vein (Contegra).
This retrospective study looked at 40 years of experience of
treating CAT with homograft reconstruction of the RVOT.
Surgical intervention in patients with CAT is often chal-
lenging, with a significant mortality if prompt treatment is
not instigated. In our sample of 32 patients, there were 3
(9.3%) early inpatient deaths and 24 (90.7%) long-term sur-
vivors. This is broadly in agreement with other studies,
which have demonstrated similar early mortality rates,
with the majority of deaths occurring in the early postoper-
ative period.14,16,19 The actuarial survival in our study was
83.1%  6.6% at 30 years, indicating that the majority of
patients with CAT survive long term. Similar but less
efficacious results have been reported in the literature,
with one study demonstrating an 83% actuarial survival at
15 years postoperatively.13 Other studies with shorter
follow-up periods have reported actuarial survival figures
of 93% at 6 years and 96% at 3 years.14,20 Our excellent
long-term survival figures could be attributed to a relatively
low incidence of complications, good hemodynamics, and
the need for infrequent reintervention in the CAT patient
population.
At the time of primary CAT surgery, in the first few
months of life, the small size of the heart necessitates the
use of a comparably small RVOT reconstruction graft.
With advancing age, patients are at risk of outgrowing their
graft, resulting almost inevitably in graft failure and the need
for reintervention. Indeed, 10-year freedom from explanta-
tion is greater when a larger homograft (>19 mm) is used328 The Journal of Thoracic and Cardiovascular Surgat the initial operation.4 Other factors also influence the like-
lihood of early RVOT graft failure and include graft steno-
sis, calcification, and infective endocarditis. Reoperation
for graft failure can be technically difficult and carries
with it a significant risk of morbidity and mortality. Increas-
ing the time to graft reintervention is thus an important goal
in the management of patients with CAT. In our study com-
prising a follow-up of up to more than 40 years, 19 (67%)
patients required reintervention for homograft failure,
some more than once. Replacement of the homograft was
the treatment of choice in most patients. Other studies
have demonstrated similar actuarial freedom from reopera-
tion figures over similar follow-up periods.21-23
Homografts thus seem to offer good durability with a low
incidence of failure when used in patients with CAT.
Several studies have compared homografts with Contegra
bovine jugular vein grafts for RVOT reconstruction.11,12
Freedom from graft dysfunction and reoperation was
comparable in these 2 groups up to a maximum follow-up
time of 7 years. However, these studies looked at a mixed
patient population and not solely patients with CAT over
a comparatively short timeframe.
Truncal valve regurgitation is often cited as a predictor of
poor outcome after surgical intervention for CAT, especially
when associated with an interrupted aortic arch.13,21,24 Our
policy for first-time surgical intervention is to repair the
truncal valves by either tricuspidizing a quadricuspid valve
or repair of the bicuspid valve if there is moderate-
to-severe regurgitation. Truncal valve replacement is also
an appropriate management option that can be accomplished
with either mechanical prostheses or valved aortic homo-
grafts. In our series 1 (33%) of the 3 cases of early mortality
was attributed to severe truncal valve regurgitation. Of the
28 long-term survivors, only 5 (17.8%) had truncal valve in-
competence, with excellent overall freedom from truncal
valve reoperation at both 10 and 30 years. These patients
also took a comparatively long time (10.5 years) to require
truncal valve replacement. The 6 truncal valve replacements
were performed during follow-up after primary repair of
CAT. The regurgitation grade at the time of the initial repair
was none to mild in these patients. We assessed all these
valves for repair first during surgical intervention. However,
in this redo setting our threshold for replacement was low for
these very dysplastic valves and hence the replacements.
Other authors have reported similar freedom from truncal
valve reoperation, with a shorter time to reoperation if trun-
cal insufficiency was present before initial repair.13,25
Truncal insufficiency and stenosis can be associated with
progressive left ventricular dysfunction. In the patients in
our study who did not require truncal valve replacement
by final follow-up, the vast majority demonstrated good he-
modynamics with low truncal gradients and minimal regur-
gitation across the truncal valve. A reason for this might be
appropriate and prompt selection of patients in need ofery c August 2010
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Dtruncal valve replacement in our series. However, it is more
likely that truncal valves actually perform well and have
good long-term hemodynamics in a majority of patients.
Indeed, left ventricular function was preserved in most
patients, whereas there was a low incidence of physical
symptoms of cardiac failure.
This study should be interpreted in light of its limitations.
The study is retrospective and contains smaller numbers of
patients. However, CAT is an uncommon cardiac anomaly,
and case series such as this one from single specialist centers
are important for expanding our knowledge of the subject.
This study has looked at the outcomes of using homo-
grafts in the primary repair of CAT. We have demonstrated
that long-term survival is excellent, and patients can expect
roughly 12 years of freedom from reoperation for homograft
failure. Reintervention for truncal valve complications is
also uncommon among these patients and, if needed, occurs
around 10 years from primary repair. The long-term func-
tional outcomes in terms of left ventricular dysfunction
and symptoms of cardiac failure are also impressive.
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